Literature DB >> 18307377

Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.

Stephen V Faraone1, Timothy E Wilens.   

Abstract

The objective of this article is to review literature about the effects of stimulant therapy on substance use disorders and the potential for misuse and diversion of stimulants. We reviewed published literature relevant to these objectives, and studies were selected if they were published or accepted for publication in peer-reviewed journals. Prospective longitudinal studies show that attention-deficit/hyperactivity disorder (ADHD) is a risk factor for subsequent substance use disorders. These studies also suggest that ADHD pharmacotherapy in childhood reduces the risk for substance use disorders. Misuse and diversion of prescribed stimulants occur among a minority of ADHD patients, especially those with conduct or substance use disorders. Long-acting stimulants may be less likely to be misused or diverted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18307377

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  25 in total

1.  Stimulant ADHD medication and risk for substance abuse.

Authors:  Zheng Chang; Paul Lichtenstein; Linda Halldner; Brian D'Onofrio; Eva Serlachius; Seena Fazel; Niklas Långström; Henrik Larsson
Journal:  J Child Psychol Psychiatry       Date:  2013-10-25       Impact factor: 8.982

2.  Early-life risperidone enhances locomotor responses to amphetamine during adulthood.

Authors:  Bobbie Lee Stubbeman; Clifford J Brown; Justin R Yates; Mark E Bardgett
Journal:  Eur J Pharmacol       Date:  2017-07-14       Impact factor: 4.432

3.  Sex differences in the behavioral response to methylphenidate in three adolescent rat strains (WKY, SHR, SD).

Authors:  Mircea I Chelaru; Pamela B Yang; Nachum Dafny
Journal:  Behav Brain Res       Date:  2011-08-25       Impact factor: 3.332

4.  Often Overlooked and Ignored, but Do Not Underestimate Its Relevance: ADHD in Addiction - Addiction in ADHD.

Authors:  Arnt F A Schellekens; Wim van den Brink; Falk Kiefer; Anneke E Goudriaan
Journal:  Eur Addict Res       Date:  2020-07-02       Impact factor: 3.015

5.  Prospective relationships of ADHD symptoms with developing substance use in a population-derived sample.

Authors:  E Sihvola; R J Rose; D M Dick; T Korhonen; L Pulkkinen; A Raevuori; M Marttunen; J Kaprio
Journal:  Psychol Med       Date:  2011-05-20       Impact factor: 7.723

6.  Cross-generational transmission from drug abuse in parents to attention-deficit/hyperactivity disorder in children.

Authors:  K S Kendler; H Ohlsson; K Sundquist; J Sundquist
Journal:  Psychol Med       Date:  2016-04       Impact factor: 7.723

7.  Attention-deficit/hyperactivity disorder and risk for drug use disorder: a population-based follow-up and co-relative study.

Authors:  J Sundquist; H Ohlsson; K Sundquist; K S Kendler
Journal:  Psychol Med       Date:  2014-08-14       Impact factor: 7.723

8.  Medication for Attention-Deficit/Hyperactivity Disorder and Risk for Depression: A Nationwide Longitudinal Cohort Study.

Authors:  Zheng Chang; Brian M D'Onofrio; Patrick D Quinn; Paul Lichtenstein; Henrik Larsson
Journal:  Biol Psychiatry       Date:  2016-02-23       Impact factor: 13.382

9.  A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD.

Authors:  Earle E Bain; Weining Robieson; Yili Pritchett; Tushar Garimella; Walid Abi-Saab; George Apostol; James J McGough; Mario D Saltarelli
Journal:  Neuropsychopharmacology       Date:  2012-10-03       Impact factor: 7.853

Review 10.  European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.

Authors:  Sandra J J Kooij; Susanne Bejerot; Andrew Blackwell; Herve Caci; Miquel Casas-Brugué; Pieter J Carpentier; Dan Edvinsson; John Fayyad; Karin Foeken; Michael Fitzgerald; Veronique Gaillac; Ylva Ginsberg; Chantal Henry; Johanna Krause; Michael B Lensing; Iris Manor; Helmut Niederhofer; Carlos Nunes-Filipe; Martin D Ohlmeier; Pierre Oswald; Stefano Pallanti; Artemios Pehlivanidis; Josep A Ramos-Quiroga; Maria Rastam; Doris Ryffel-Rawak; Steven Stes; Philip Asherson
Journal:  BMC Psychiatry       Date:  2010-09-03       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.